Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR

Pharmacogenomics

Volumn 12, Issue 4, 2011, Pages 567-576

  Dello Russo, Cinzia ^a   Lisi, Lucia ^a   Lofaro, Alessia ^a   Di Giambenedetto, Simona ^a   Federico, Bruno ^b   Madeddu, Giordano ^c   Salerno, Marianna ^c   Mura, Maria Stella ^c   Pirazzoli, Antonella ^d   De Luca, Andrea ^a,e   Cauda, Roberto ^a   Navarra, Pierluigi ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF CASSINO AND SOUTHERN LAZIO   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

^d VIIV HEALTHCARE   (United States)

^e UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

abacavir; HIV 1; HLA B*57:01; hypersensitivity reaction; pharmacogenomic test; real time PCR

Indexed keywords

ABACAVIR; HLA B57 ANTIGEN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA SEQUENCE; DRUG HYPERSENSITIVITY; GENE AMPLIFICATION; HUMAN; INTERMETHOD COMPARISON; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; PREDICTION; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SCREENING TEST; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; VALIDATION PROCESS; VALIDITY;

ANTI-HIV AGENTS; BASE SEQUENCE; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; HIV INFECTIONS; HLA-B ANTIGENS; HUMANS; MOLECULAR SEQUENCE DATA; PHARMACOGENETICS; POLYMERASE CHAIN REACTION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79955535238     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.208     Document Type: Article

References (21)

1. Martinez-Cajas JL, Wainberg MA: Antiretroviral therapy: optimal sequencing of therapy to avoid resistance. Drugs 68, 43-72 (2008). (Pubitemid 350275684)
2. Sabin CA, Worm SW, Weber R et al.: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371, 1417-1426 (2008).
3. Currier JS: Update on cardiovascular complications in HIV infection. Top HIV Med. 17, 98-103 (2009).
4. Chessman D, Kostenko L, Lethborg T et al.: Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 28, 822-832 (2008). (Pubitemid 351784513)
5. Lucas A, Nolan D, Mallal S: HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. J. Antimicrob. Chemother. 59, 591-593 (2007). (Pubitemid 47073389)
6. Mallal S, Nolan D, Witt C et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727-732 (2002). (Pubitemid 34215071)
7. Hetherington S, Hughes AR, Mosteller M et al.: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121-1122 (2002). (Pubitemid 34270738)
8. Saag M, Balu R, Phillips E et al.: Study of hypersensitivity to abacavir and pharmacogenetic evaluation study team. High sensitivity of human leukocyte antigen-B*57:01 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin. Infect. Dis. 46, 1111-1118 (2008). (Pubitemid 351589880)
9. Mallal S, Phillips E, Carosi G et al.; PREDICT-1 Study Team: HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-579 (2008). (Pubitemid 351214284)
10. Hammer SM, Eron JJ Jr, Reiss P et al.; International AIDS Society-USA: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300, 555-570 (2008).
11. Clumeck N, Pozniak A, Raffi F; EACS Executive Committee: European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 9, 65-71 (2008). (Pubitemid 351228129)
12. Martin AM, Nolan D, Mallal S: HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing. Tissue Antigens 65, 571-574 (2005). (Pubitemid 40776308)
13. Lalonde RG, Thomas R, Rachlis A et al.: Successful implementation of a national HLA-B*5701 genetic testing service in Canada. Tissue Antigens 75, 12-18 (2010).
14. Giardina E, Stocchi L, Foti Cuzzola V et al.: A fluorescence-based sequence-specific primer PCR for the screening of HLA-B*57:01. Electrophoresis 31, 3525-3530 (2010).
15. Orkin C, Sadiq ST, Rice L, Jackson F: Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects. HIV Med. 11, 187-192 (2010).
16. Cereb N, Maye P, Lee S, Kong Y, Yang SY: Locus-specific amplification of HLA class I genes from genomic DNA: locus-specific sequences in the first and third introns of HLA-A, -B, and -C alleles. Tissue Antigens 45, 1-11 (1995).
17. Robinson J, Mistry K, McWilliam H, Lopez R, Parham P, Marsh SG: The IMGT/HLA Database. Nucleic Acids Res. 39(Database issue), D1171-D1176 (2011).
18. Cohen J: A coefficient of agreement for nominal scales. Edu. Psych. Measur. 20, 37-46 (1960).
19. Hammond E, Mamotte C, Nolan D, Mallal S: HLA-B*5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay. Tissue Antigens 70, 58-61 (2007). (Pubitemid 46890273)
20. Middleton D, Menchaca L, Rood H, Komerofsky R: New allele frequency database. Tissue Antigens 61, 403-407 (2003).
21. Dello Russo C, Lisi L, Lofaro A et al.: Validation of a sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: detection of HLA-B*5701 by real-time PCR. Infection 38(Suppl. 1), 61 (2010) (Abstract P040).